港股異動 | 中達集團控股大漲逾9% 擬收購廣東友倍親51%股權 尋求多元化
格隆匯2月22日丨中達集團控股大漲逾9%,報0.024港元,近兩週累積漲幅達140%,成交額884萬港元。中達集團控股昨日公吿,公司間接全資子公司深圳中達企業諮詢有限公司以人民幣1元收購股東深圳友倍親持有的廣東省友倍親51%的股權共人民幣255萬元出資額。廣東省友倍親成為集團的非全資附屬公司。廣東省友倍親未來將與集團共同合作,致力打造一家從事綜合門診、中醫診所、中藥膏方研發、私護凝膠生產、醫療管理培訓的綜合型醫藥公司。聯營店將與現有中醫診所合併,與美容院,養生會所合作,低門檻加盟,快速發展同時擁有原有客户基數,最終達到雙方共贏。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.